
Current Price | $150.81 | Mkt Cap | $263.5B |
---|---|---|---|
Open | $150.36 | P/E Ratio | 21.28 |
Prev. Close | $149.11 | Div. (Yield) | $5.64 (3.8%) |
Daily Range | $149.79 - $152.99 | Volume | 1,816,374 |
52-Wk Range | $105.56 - $175.91 | Avg. Daily Vol. | 7,697,803 |
Current Price | $150.81 | Mkt Cap | $263.5B |
---|---|---|---|
Open | $150.36 | P/E Ratio | 21.28 |
Prev. Close | $149.11 | Div. (Yield) | $5.64 (3.8%) |
Daily Range | $149.79 - $152.99 | Volume | 1,816,374 |
52-Wk Range | $105.56 - $175.91 | Avg. Daily Vol. | 7,697,803 |
The best Bull and Bear pitches based on recency and number of recommendations.
Good new drugs coming on line to replace the profits that came from Humira
This mega-cap has made a big run since Express Scripts's announcement that it will take AbbVie's hep C treatment in lieu of Gilead's. Also, an amazing preponderance of CAPS bulls favor this stock beating the market from here -- very interesting. For… More
Read the most recent pitches from players about ABBV.
Recs
Earnings Growth; a solid dividend of $5.64 per share; and a Pharma manufact. market with a CAGR of 11.34% through 2028.
Recs
Good new drugs coming on line to replace the profits that came from Humira
Recs
Despite AbbVie's near-term headwinds relating to the upcoming loss of exclusivity of Humira in the U.S., the company boasts promising drugs in its oncology and immunology segments. Venclexta has 3 different indications that are anticipated to be approved by next year. In addition, the stock appears to be trading at a discount to fair value with an attractive 4.4% dividend yield.
Find the members with the highest scoring picks in ABBV.
concealedweaponR (< 20) Score: +386.50
The Score Leader is the player with the highest score across all their picks in ABBV.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
armydave | 48.46 |
|
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment | |
pirotta | < 20 | 1/10/2013 |
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment | |
deliman723 | 67.47 | 1/10/2013 |
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment | |
concealedweaponR | < 20 | 1/10/2013 |
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment | |
drjohn432 | < 20 |
|
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment | |
![]() |
valari25 | 99.70 |
|
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment |
![]() |
GW1000 | 85.68 |
|
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment |
![]() |
mattmmurphy | 72.51 | 1/10/2013 |
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment |
cooleyly | 59.85 | 1/10/2013 |
![]() |
5Y | $23.06 | +555.99% | +169.49% | +386.50 | 0 Comment | |
![]() |
kinosternon | 98.81 | 1/9/2013 |
![]() |
5Y | $23.17 | +553.02% | +170.74% | +382.28 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.